JASPER THERAPEUTICS, INC. Derivative Liability
JASPER THERAPEUTICS, INC. (JSPR) had Derivative Liability of $10.43 million as of 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2022-03-18
- 2021-06-30: Derivative Liability $10.43M.
- 2021-03-31: Derivative Liability $7.42M.
- 2020-12-31: Derivative Liability $8.16M; Derivative Liability as first filed $13.13M.
- 2019-12-31: Derivative Liability $7.24M.
| Period end | Derivative Liability | Derivative Liability as first filed |
|---|---|---|
| 2021-06-30 | $10.43M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $7.42M 10-Q · filed 2021-05-24 | |
| 2020-12-31 | $8.16M 10-K · filed 2022-03-18 | $13.13M 10-K/A · filed 2021-05-24 |
| 2019-12-31 | $7.24M 10-K/A · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |